Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $106 | In Stock | |
5 mg | $263 | In Stock | |
10 mg | $428 | In Stock | |
25 mg | $872 | In Stock | |
50 mg | $1,450 | In Stock | |
100 mg | $2,320 | In Stock |
Description | Clk1-in-3 is a + selective and highly potent sexual Clk1 inhibitor with an IC50 of 5 nM and 300 pairs higher affinity than Dyrk1A. CLK1-IN-3 also showed highly effective inhibition of Clk2 and Clk4, with IC50 values of 42 and 108 nM, respectively. CLK1-IN-3 is effective in inducing autophagy in vitro and can be used for prevention and human treatment of acute liver injury (ALI). |
In vitro | CLK1-IN-3 (compound 10ad) demonstrates anti-tumor potential due to its dual inhibitory effects on Clk1 and Clk2[1]. CLK1-IN-3 (10 μM-1000 μM) effectively binds to the Clk1 protein and inhibits its degradation in a dose-dependent manner[1]. CLK1-IN-3 (0-10 μM, 24 h) induces autophagy in Hela, BNLCL.2, and HCT 116 cells[1]. CLK1-IN-3 stimulates the degradation of SQSTM1/p62 (autophagy marker)[1]. |
In vivo | CLK1-IN-3 (0-40 mg/kg, intraperitoneal injection, single dose) significantly inhibits acute liver injury induced by acetaminophen (APAP) in the ALI model, and there is no apparent hepatocyte death observed[1]. CLK1-IN-3 (10 mg/kg; intravenous injection, oral administration, intraperitoneal injection, single dose) exhibits acceptable pharmacokinetic characteristics, with a relatively long half-life (T1/2) of 5.29 hours and an oral bioavailability of 19.5%[1]. |
Molecular Weight | 430.48 |
Formula | C24H23FN6O |
Cas No. | 2922550-28-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 55 mg/mL (127.76 mM) ![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.